Market capitalization | CHF20.27b |
Enterprise Value | CHF22.58b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 84.13 |
EV/Sales (TTM) EV/Sales | 5.94 |
P/S ratio (TTM) P/S ratio | 5.34 |
P/B ratio (TTM) P/B ratio | 2.96 |
Revenue (TTM) Revenue | CHF3.80b |
EBIT (operating result TTM) EBIT | CHF526.40m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
12 Analysts have issued a Galderma forecast:
12 Analysts have issued a Galderma forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3,799 3,799 |
-
|
|
Gross Profit | 2,632 2,632 |
-
|
|
EBITDA | 781 781 |
-
|
EBIT (Operating Income) EBIT | 526 526 |
-
|
Net Profit | -12 -12 |
-
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Flemming Ørnskov |
Employees | 6,545 |
Website | www.galderma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.